NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
The US pauses use of JNJ-78436735 after six cases of cerebral venous sinus thrombosis.
The first quarter of 2021 saw fewer deals than any in recent memory.
Evaluate Vantage's coverage of the virtual AACR 2021 congress.
Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.
And consolidation in the diagnostics space is only just beginning.
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The quest for the Grail is beset with challenges.